ArticleJCEM case reports2026
Elagolix as a Diagnostic and Therapeutic Bridge to Surgery in Refractory Progestogen Hypersensitivity.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progestogen hypersensitivity (PH) is a rare and underrecognized condition characterized by cyclical allergic reactions to endogenous or exogenous progestogens. We present a 27-year-old woman with an 11-year history of recurrent luteal-phase urticaria, angioedema, and anaphylaxis refractory to antihistamines, corticosteroids, and hormonal suppression. She was diagnosed with PH at age 21. Introduction of elagolix, a GnRH antagonist, led to marked symptomatic improvement by suppressing ovarian hormone production. Due to cost and side effects, definitive surgical management with total laparoscopic hysterectomy and bilateral salpingo-oophorectomy was performed, resulting in complete remission. Fewer than 200 cases are reported in the literature, and standardized diagnostic or treatment protocols are lacking. This case highlights the diagnostic complexity of PH, the therapeutic potential of GnRH antagonists as a bridge to surgery, and the importance of a multidisciplinary approach. It underscores the need for greater awareness, standardized diagnostic criteria, and further research into the immunologic mechanisms underlying PH to guide future management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.